Introduction
The FGF receptor tyrosine kinase (RTK) family consisting of FGFR1, FGFR2, FGFR3 and FGFR4, encompasses the high affinity receptors for 18 different FGF ligands. These ligand-receptor combinations regulate a broad spectrum of signaling and endocrinological activities during development and in adult tissue homeostasis (1) . In keeping with the importance of FGFR in normal growth control, de-regulated FGF signaling has been linked to diseases, most prominently in the pathogenesis of multiple cancers. Epidemiological and molecular studies have revealed a variety of genetic alterations in components of the FGF/FGFR signaling system, resulting in aberrant receptor activation and thus, enhanced downstream signaling.
The underlying genetic alterations are largely tissue specific and include gene amplifications, translocations and point mutations. Evidence for gene copy number changes has been reported in several studies. In particular, Beroukhim et al 2010, analyzed somatic copy-number alterations in 3,131 cancer specimens and found that FGFR1 was significantly focally amplified across the entire dataset with a GISTIC q-value of 9.05E-47, and was located within a region of focal amplification containing only FGFR1, LETM2 and WHSC1L1 (2) . In breast cancer FGFR1 is preferentially amplified in estrogen receptor-positive tumors as demonstrated by chromosome in situ hybridization, and survival analysis indicates that it may also be an independent prognostic factor for poor outcome (3) . Furthermore, high resolution gene copy number analysis in lung cancer revealed FGFR1 amplification preferentially in the squamous subtype (4, 5) . FGFR2 copy number gains, albeit with a low incidence, were reported in breast tumors (6, 7) and in gastric cancer in particular in poorly differentiated adenocarcinomas (8) (9) (10) (11) . Among the ligands, FGF19 located in the common 11q13 amplicon was recently identified to be a driver gene in liver cancer in cooperation with its neighboring gene cyclin D1 (12) . Germline mutations in FGFR1, FGFR2 and FGFR3 were first discovered as causative lesions in skeletal dysplasias (13). Kinome exon sequencing in search of human cancer somatic mutations, identified FGF signaling components as the most frequently mutated coding regions among protein kinases (14) . Somatic mutations of FGFR1 have been found in gliomas and lung tumors (15, 16) , of FGFR2 in gastric and endometrial carcinomas (17) (18) (19) , of FGFR3 in bladder carcinomas and multiple myeloma (20, 21) , and of FGFR4 were reported in primary rhabdomyosarcomas (22) .
In addition, studies of hematological malignancies have led to the characterization of chromosomal translocations involving FGFR genes. In particular, FGFR1 intragenic translocations between the Nterminus of a transcription factor and the FGFR1 kinase domain leading to constitutive kinase activation by oligomerization are responsible for 8p11 myeloproliferative disorder (23) . Similar translocations of FGFR3 are associated with peripheral T-cell lymphoma (24) , while in multiple myeloma recurrent chromosomal translocations of 14q32 into the immunoglobuling heavy chain switch region result in deregulated ectopic expression of FGFR3 and the adjacent multiple myeloma SET domain-containing (MMSET) gene (21) .
Based on the evidence of broad genetic alteration of the FGF/FGFR system in cancer, we hypothesized that targeted inhibition of FGFRs would be an attractive modality for therapeutic intervention across multiple indications bearing such specific underlying genetic alterations. To this end, we have developed NVP-BGJ398, a potent orally bioavailable, small molecule pan-FGFR kinase inhibitor which is currently in clinical Phase I trial (25) . In order to preclinically identify and validate patient stratification 6 expression, gene copy number alterations and gene mutations (26) . In addition, over half of these cell lines were subjected to high-throughput cell viability assays, upon exposure to hundreds of compounds representing a variety of mechanisms of action, including the FGFRs inhibitor NVP-BGJ398. Analysis of these cell lines sensitivity profiles revealed that NVP-BGJ398 significantly inhibits proliferation of cancer cell lines bearing FGF/FGFR genetic alterations across various cancer types, thus pre-clinically validating the hypothesis that a defined patient selection strategy based on tumors harboring FGF/FGFR genetic alterations is likely to enrich for responses to NVP-BGJ398.
Research. 
Results

NVP-BGJ398 is a potent and selective FGFR kinase inhibitor
NVP-BGJ398 is a N-aryl-N'-pyrimidin-4-yl urea derivative that was designed by applying a new and non-conventional strategy to mimic the pyrido [2,3-d] pyrimidin-7-one core structure of a well-known class of protein kinase inhibitors (Fig. 1A) (25, 27) . The proposed binding mode of NVP-BGJ398 was elucidated by solving the three-dimensional structure of the FGFR1 kinase domain in complex with BGJ398 (Fig. 1B) . As shown in Fig. 1B , the 4-(4-ethyl-piperazin-1-yl)-phenylamine NH and the adjacent pyrimidine nitrogen are involved in critical H-bonds with the carbonyl and the amino group of alanine 564 (an amino acid residue located in the hinge region of the ATP-binding pocket), respectively.
The urea carbonyl group is engaged in a water-mediated H-bond with the side chain amino group of lysine 514, whereas the aryl ring of the 4-(4-ethyl-piperazin-1-yl)-phenylamine is in contact with the hydrophobic side chains of two amino acid residues glycine 567 and leucine 484 (the former not represented for clarity) in a sandwich-like manner. The 2,6-dichloro-3,5 dimethoxy-aniline fills optimally the complementary cavity in the kinase. Indeed, the perpendicular orientation of the tetrasubstituted benzene ring with respect to the plane of the pesudo bicyclic system enforced by the two chlorine atoms allows productive hydrophobic interactions with several amino acid residues. In addition, this same ring is responsible for an H-bond between the methoxy oxygen and the NH of aspartate 641.
NVP-BGJ398 was tested against the four FGFRs and a panel of additional kinases in biochemical and cellular assays. NVP-BGJ398 inhibited FGFR1, FGFR2 and FGFR3 with single digit nM IC50s in biochemical and cellular autophosphorylation assays and FGFR4 with 38 to 60-fold lower potency ( Fig.   1C and D; Suppl. Table S1 ). In cellular viability assays using a panel of BaF3 cell lines rendered IL-3 independent by various tyrosine kinases, the most potently inhibited kinase, in addition to the FGFRs was found to be VEGFR2, displaying 70-to 100-fold reduced potency compared to FGFR1, FGFR2 and FGFR3. Therefore, NVP-BGJ398 is a selective, pan-FGFR kinase inhibitor, with predominant activity on FGFR1, -R2 and -R3.
Predicting responses to NVP-BGJ398 by means of the Cancer Cell Line Encyclopedia (CCLE)
Activation of the FGFR pathway is a common feature in human cancers with underlying genetic abnormalities in the FGF/FGFR system (28) . To test whether tumors presenting these abnormalities depend on FGFR kinase activity, and hence would be sensitive to NVP-BGJ398, and to eventually elucidate predictive patient selection biomarkers for clinical trials with NVP-BGJ398, the antiproliferative activity of NVP-BGJ398 was assayed in a panel of 541 cell lines from the Cancer Cell Line Encyclopedia (CCLE). From two independent high throughput cell viability screens encompassing 435 and 424 cell lines respectively, with about 80% overlap, cell viability data in triplicate met the quality criteria for NVP-BGJ398 across a total of 517 cell lines (Suppl. File 1). Analysis of cell lines distribution with respect to the Amax and inflection point values for NVP-BGJ398 across the entire cell viability dataset, indicates that a subgroup of cell lines is highly sensitive (n=35) to the compound, while the large majority of cell lines (n=482) are insensitive (Suppl. Fig. S1A ). Sensitive and non-sensitive groups were defined according to specific cut-off values for Amax and Inflection point. To mitigate the risk of missing sensitive cell lines because of the accuracy limitations of a high throughput screening mode, the thresholds for sensitivity in a first filtering step were set at relatively low stringency, with Amax -40 and inflection point 1uM. In order to validate the sensitive response calls to NVP-BGJ398, the 35 cell lines fulfilling the above selection criteria (lower left quadrant in Suppl. Fig. S1A) were tested in subsequent viability assays manually.
In order to define the range of on-target FGFR-dependent inhibition of cell proliferation, the IC50 values obtained in cell viability assays for BaF3 cells rendered dependent on the specific FGFRs were used as a reference. Based on this, only cancer cell lines whose proliferation was inhibited with IC50s < 500 nM were classified as sensitive. Among the 35 cell lines selected from the high throughput assays, 28 were confirmed sensitive to NVP-BGJ398 with IC50s ranging from 0.001 nM to 500 nM (Suppl. Fig. S1B ).
Additional 24 selected lines from the CCLE, for which high throughput cell line profiling data were not available, were also tested in manual cell proliferation assays and 4 of them were found to be sensitive to the FGFR inhibitor (Suppl. Fig. S1B ). Collectively, among the 541 (517 + 24) cell lines from the CCLE subjected to viability testing, 5.9% (encompassing 13 different cancer types) were found to be sensitive to NVP-BGJ398, when an IC50 cut-off of 500 nM for on-target inhibition of cell proliferation was applied (Fig. 2) .
In order to derive molecular correlates of drug sensitivity, we utilized a predictive categorical model approach as described (26) . The feature matrix examined in this approach encompassed: all CCLE genomic data as single genomic features (expression, copy number, COSMIC mutation data), 25 lineage features, 1777 "GeneSet" features (expression signatures each of them consisting of multiple genes), and a composite "FGFR genetic alteration" feature consisting of 8 distinct types of FGFR genetic alterations: FGFR1, -R2, -R3 and -R4 copy number gains, activating mutations in FGFR1, -R2, and -R3, as well as the chromosomal translocations for either FGFR1 or -R3 previously reported in the literature (21, 29) .
From >50,000 input features, this analysis identified the "FGFR genetic alteration" feature as the top predictor for response to NVP-BGJ398 followed by two mutation features and two "GeneSet" features (Fig. 3A, 3B ). As indicated in Fig. 2 , within the 541 cell lines used in the analysis, only 37 were found to bear genetic abnormalities for either of the FGFRs (total of 6.8%), in line with the general low incidence of these genetic lesions in tumors. Among those, 17 cell lines were sensitive to NVP-BGJ398, representing 53% of all cell lines testing sensitive to the drug (17/32, Supp. Table S2 ). In contrast, in the . Table   S3 ). Interestingly, the GeneSet expression signatures-positive cell lines comprised most of the NVP-BGJ398 sensitive cell lines with FGFR genetic alterations, as well as most of the sensitive ones for which no FGFR genetic abnormalities were identified (Supp. Fig. S3A ). Conversely, many of the insensitive cell lines harboring FGFR genetic alterations were GeneSet signature negative or had a low z-score (Supp. Fig. S3B ).
FGFR1 amplification is associated with response to NVP-BGJ398
Since NVP-BGJ398-sensitive FGFR amplified cell lines were captured by the "FGFR genetic alteration" and "GeneSets" features, we examined further these genomic features across the CCLE.
FGFR1 copy number gain defined as log2ratio 1 (equal to 4 normalized DNA copies) was observed in cell lines of breast, lung and osteosarcoma lineages ( In keeping with the high levels of FGFR2 gene expression, FGFR2-amplified gastric (KATOIII and SNU16) and colon (NCI-H716) cancer lines showed strong baseline activity of the FGFR pathway, which was modulated upon NVP-BGJ398 treatment (Fig. 5C ), and were dependent on FGFR signaling for proliferation, as evident from the low nanomolar IC50 for NVP-BGJ398 (Supp . Table S2 ).
In agreement with inhibition of in vitro proliferation, NVP-BGJ398 also effectively inhibited growth of SNU16 tumor xenografts in a dose-dependent manner when administered orally to rats on a daily schedule (Fig. 5D ). Tumor growth inhibition was correlated with inhibition of FGFR2 tyrosine phosphorylation in tumor tissue (Fig. 5E) , which was almost completely abolished at 3 hours post- Thus, FGFR2 amplified cell lines are sensitive to NVP-BGJ398 in vitro as well as when grown in vivo as human tumor xenografts. Hence we envision that human gastric tumors harboring FGFR2 amplification will be responsive to NVP-BGJ398 in the clinic. Interestingly, in addition to confirming the incidence of this genetic alteration in gastric cancer, we also found FGFR2 amplification in 1 of 22 oesophageal tumors, which offers a novel potential clinical opportunity for an FGFR inhibitor (Supp Fig. S4B ).
FGF19 amplification in liver cancer correlates with response to NVP-BGJ398
Approximately 47% cell lines responsive to NVP-BGJ398 did not harbor FGFR genetic alterations.
Among those, the gene encoding for the FGF19 ligand was found to be amplified (log2ratio 1) in the liver cancer cell lines HUH7, HEP3B and JHH7 (Fig. 7A) , as previously reported (12) . The analysis of The three sensitive liver cancer cell lines showed constitutive FRS2 Tyr-phosphorylation, which was abolished upon treatment with NVP-BGJ398 at doses of 50 nM (Fig. 7B) . In hepatocytes and liver cancer cells, FGF19 has been shown to signal through FGFR4 (31) . In line with these findings, we found that the three cell lines expressed significantly high levels of FGFR4 mRNA (Fig. 7A ) and conditional silencing of FGFR4 with three different shRNAs in the JHH7 cell line, previously shown to require FGF19 for survival, led to significant inhibition of cell proliferation (Fig. 7C, D) .
Thus, these results suggest that while most cancers with 11q13 amplification may not respond to 
Discussion
In this study we have identified patient selection strategies for NVP-BGJ398, a novel selective pan-FGFR kinase inhibitor currently in Phase I clinical trials in cancer patients. In order to guide patient selection and to maximize the likelihood of patient benefit and successful clinical proof of concept for this novel targeted anti-cancer modality, we have analyzed the sensitivity of over 500 cell lines from the CCLE to NVP-BGJ398 in cell viability assays, and intersected response data with information on gene expression and genomic alterations. We show that NVP-BGJ398 inhibits proliferation of about 6% of the cancer cell lines tested at concentrations that are consistent with its mechanism of action and in line with the its highly selective nature. Further, the integrative analysis of the CCLE has revealed "FGFR genetic alteration" as the top predictor for response to NVP-BGJ398 among over 50,000 input features containing genomic, lineage and geneset features.
Indeed, amongst the 541 cell lines in the CCLE with pharmacological drug sensitivity data, 37 harbored an FGFR genetic alteration and 17 of them were sensitive to NVP-BGJ398, i.e. 53% of the total cell lines responding to the drug (17/32). Gene amplifications were most prevalent (10/17) and involved FGFR1, FGFR2 and surprisingly also FGFR3, followed by sequence variations in FGFR2 and FGFR3 (6/17), and chromosomal translocations affecting FGFR1 and FGFR3 (3/17). High resolution SNP6.0 array data across the CCLE subjected to analysis with the GISTIC algorithm revealed that the FGFR1 locus lies in a focal peak region of amplification, whereas FGFR2 was found in a GISTIC peak when the analysis was restricted to the gastric cancer cell lines (32). In this setting, NVP-BGJ398 response was associated in a statistically significant manner with both, FGFR1 amplification and FGFR2 amplification. These data confirmed the finding of FGFR1 and FGFR2 copy number alterations in breast, lung and gastric cancer cell lines as previously reported (5, 6, 9) , but it also revealed the occurrence of these genetic lesions in additional cancer types, such as osteosarcoma and colon 
respectively. In this context among the 7 osteosarcoma lines in the CCLE, the one harboring FGFR1 amplification (G292) was significantly growth suppressed under both monolayer and soft agar conditions upon inducible knock down of FGFR1 by two distinct shRNAs, consistent with the notion that amplified FGFR1 confers cancer dependence. In addition, and for the first time, we report FGFR1 amplification in 1/17 primary osteosarcomas suggesting that this may be another potential indication for an FGFR inhibitor. Similarly, the only colon cancer cell line NCI-H710 with high level FGFR2 amplification was sensitive to NVP-BGJ398. In line with the notion that FGFR2 is a driver oncogene when its locus is aberrantly amplified, we selected human primary gastric tumors for the presence of FGFR2 copy number alterations and confirmed them to be exquisitely responsive to the selective FGFR inhibitor NVP-BGJ398, whereas models with normal FGFR2 DNA copy number were insensitive to the drug (data not shown). In agreement with previous analyses of FGFR2 copy number alterations performed by FISH (8, 9) or Southern blot (11), we have found high level amplifications (CN > 10) of FGFR2 by means of Q-PCR in 5% of gastric tumors among a total of 147 specimens, and in 1 of 22 oesophageal tumors, not previously reported, thus providing additional new opportunities for the therapeutic application of an FGFR inhibitor. Interestingly, we also identified FGFR3 copy number gains in three of the bladder cancer cell lines that were inhibited by NVP-BGJ398 (log2ratio 1 for RT112 and RT112/84, and log2ratio 0.94 for RT4), which may account for the significant high FGFR3 transcript expression in these cell lines (Supp Fig. S5B ). Taken together, these data supports the evaluation of NVP-BGJ398 in cancer types selected upon the presence of FGFR genes amplification.
Genomic predictors of drug sensitivity also revealed FGFR2 and FGFR3 mutation among the top three most significant features. The viability of 6 of the 9 FGFR-mutated cell lines was pharmacologically inhibited by NVP-BGJ398, they belong to the endometrial and multiple myeloma lineages and showed constitutive FGFR pathway activation (Supp. Fig. S2 ), in line with the notion that these mutations result in receptor kinase activation (17, 19, 21) . Notably, most endometrial FGFR2-mutated cell lines carried also mutations affecting either PTEN or PIK3CA (Suppl. Table 4 ), suggesting that activation of this pathway does not confer resistance to an FGFR inhibitory therapy in this cancer type. Of note, we observed constitutive AKT phosphorylation in the endometrial cancer lines, which was not affected by NVP-BGJ398 treatment (Suppl. Fig. S2) . Therefore, PI3K inhibitors may provide opportunities for combination therapy with NVP-BGJ398 in these specific settings.
Interestingly, 54% (n=20) of the FGFR genetically altered cell lines were not NVP-BGJ398-sensitive. It is likely that at least in some of these cell lines, additional genetic alterations bypass FGFR dependency.
For instance, one cell line (A375) had a BRAF V600E mutation, 10% (n=2) of the cell lines showed amplification of other oncogenes (JIMT1: HER2 amplification and NCI-H1703: PDGFRĮ amplification), while 20% (n=4) harbored KRAS mutations (Suppl. Table 4) , and KRAS mutation was revealed by the predictive model as one of the genomic predictors for NVP-BGJ398 insensitivity (data not shown). Thus, we are currently exploring whether hypothesis-driven concomitant targeting of other genetically altered molecular pathways will synergize with NVP-BGJ398 in these settings.
Alternatively, and in the case of the breast and lung FGFR1-amplified cell lines that did not respond to NVP-BGJ398, it is plausible that one of the other genes found in the GISTIC peak (LETM2, WHSC1L1) may have become the driver gene. It is also noticeable that none of the FGFR4-amplified cell lines in our data set responded to the FGFR inhibitor, thus indicating that FGFR4 is not a driver oncogene in those settings.
Conversely, several cell lines that displayed sensitivity to NVP-BGJ398 did not harbor FGFR genetic lesions. 3 of them, belonging to the liver cancer type showed copy number gain for the FGFR4 ligand, FGFR4, we showed dependency on this RTK in the JHH7 cells thus, supporting the concept of an FGF19 / FGFR4 autocrine loop as the oncogenic driver in liver cancer with FGF19 amplification. In line with the notion that this autocrine loop is only functional in the presence of the co-receptor ȕ-Klotho, which is essential for high affinity interactions of FGF19 with FGFR4 (33), we showed that only the three liver cancer cells with FGF19 amplification and concomitant ȕ-Klotho expression responded to NVP-BGJ398. This suggests that ȕ-Klotho depicts another critical determinant for patient selection, which has not been analyzed previously. Consequently, FGF19 amplification was not associated with NVP-BGJ398 response in other cancer types most likely due to the lack or low ȕ-Klotho expression. This is in line with a recent study (12) showing that FGF19 amplification correlated with increased expression and with sensitivity to FGF19 blockage only in liver cancer cell lines. 
Experimental procedures
Compound and antibodies NVP-BGJ398 has been identified and synthesized in the Global Discovery Chemistry department at NIBR (Novartis) as described (25) . For in vitro studies, 10 mM stock solutions were prepared in 100% DMSO. For in vivo studies in rodents, NVP-BGJ398 was formulated in acetic acid/acetate buffer pH 4.6 / PEG300 1:1. 
In vitro compound profiling
Biochemical in vitro kinase assays, cellular FGFR autophosphorylation assays and BaF3 cell proliferation assays were performed as described (25) .
High-throughput cell line profiling and manual cell proliferation assays
Cell lines were obtained from ATCC, DSMZ and HSSRB and cultured in RPMI or DMEM plus 10% FBS (Invitrogen) at 37°C 5% CO2 using automated processing. Cell line identities were confirmed using a 48 variant SNP panel comparing to previous cell line tests. A detailed description of the highthroughput cell viability assays can be found in Barretina et al (26) . In brief, assays were automated and performed with an ultra-high throughput screening system. Cell lines were dispensed into tissue culture (proteasome inhibitor MG132) was measured using a standard Z' factor (36) . In general nearly all responses were greater than 0.5 indicating a robust assay window. All dose-response data was reduced to a fitted model using a propriety decision tree methodology that is based on the NIH/NCGC assay guidelines (26) . Fitted models were assessed using standard Chi Squared test that was also used to determine which model to use. All data was manually reviewed as well. Parameters derived form the models include: IP, the Inflection Point of the curve; Crossing Point (CP), the concentration where the fitted curve crosses -50%; and A max , which is the maximal activity value reached within a model.
For manual cell proliferation assays, cells were seeded in 96-well plates at a density of 10 3 -10 4 cell per well in a volume of 100 μl. Media containing compound dilutions or DMSO was added 24 hours thereafter. After 72 hours or 7 days, Cell Titer Glo was added as above. The concentration of compound providing 50% of proliferation inhibition (IC50) was determined using XLfit (idbs).
Generation of stable cell lines with hairpin shRNAs
Hairpin shRNAs were cloned in pLKO-Tet-On vector to produce replication-incompetent lentiviruses as described previously (37) . Upon lentiviral infection, stable cell lines were generated by selection with puromycin (1.5 ug/ml) for 5 days. For monolayer cell proliferation assays, cells were seeded in 96-well plates and shRNAs were induced with doxycycline. Cell proliferation was evaluated by methylene blue
Genomic analysis of cell lines and primary tumors
A detailed description can be found in Barretina et al. (26) , see also (32). In brief, DNA copy number was measured using high-density single nucleotide polymorphism arrays (Affymetrix SNP6.0) and normalized to copy number estimates (log2 ratios; with log2ratio 0 being equal to 2N normalized copies) using a GenePattern pipeline (38) and hg18 Affymetrix probe annotations. Sample-specific and recurrent copy number changes were identified using the GISTIC algorithm (39) . mRNA expression levels were obtained using Affymetrix U133 plus 2.0 arrays according to the manufacturer's instructions. Gene Expression Omnibus: GSE36139
FGFR2-c3 isoform mRNA expression
The primers to specifically monitor expression of the FGFR2-C3 isoform were designed for Taqman 
